Terence Flynn
Stock Analyst at Morgan Stanley
(4.49)
# 293
Out of 5,131 analysts
237
Total ratings
63.93%
Success rate
15.35%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,290 → $1,313 | $1,040.00 | +26.25% | 24 | Feb 5, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $231.50 | +16.63% | 20 | Feb 5, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $304 → $309 | $369.19 | -16.30% | 12 | Feb 4, 2026 | |
| JNJ Johnson & Johnson | Upgrades: Overweight | $200 → $262 | $243.45 | +7.62% | 28 | Jan 28, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $23 → $20 | $18.92 | +5.71% | 9 | Jan 8, 2026 | |
| NRIX Nurix Therapeutics | Upgrades: Overweight | $15 → $36 | $15.60 | +130.77% | 7 | Jan 8, 2026 | |
| ALMS Alumis | Maintains: Overweight | $22 → $33 | $26.54 | +24.34% | 3 | Jan 7, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $26 → $21 | $11.36 | +84.86% | 5 | Jan 6, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $28 → $27 | $27.58 | -2.10% | 21 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $60.74 | -39.08% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $121.41 | -15.99% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $70.07 | +78.39% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $516 → $564 | $491.47 | +14.76% | 3 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $7.39 | +21.79% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $45.19 | +19.50% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $105.87 | +23.74% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $473.66 | -8.16% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $11.65 | -5.58% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $53.07 | -39.70% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $11.87 | -7.33% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.89 | +323.28% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $196.52 | +121.86% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $314.40 | - | 2 | Oct 2, 2017 |
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,290 → $1,313
Current: $1,040.00
Upside: +26.25%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $231.50
Upside: +16.63%
Amgen
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $304 → $309
Current: $369.19
Upside: -16.30%
Johnson & Johnson
Jan 28, 2026
Upgrades: Overweight
Price Target: $200 → $262
Current: $243.45
Upside: +7.62%
Arcus Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $18.92
Upside: +5.71%
Nurix Therapeutics
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $15.60
Upside: +130.77%
Alumis
Jan 7, 2026
Maintains: Overweight
Price Target: $22 → $33
Current: $26.54
Upside: +24.34%
Biohaven
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $11.36
Upside: +84.86%
Pfizer
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $27.58
Upside: -2.10%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $60.74
Upside: -39.08%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $121.41
Upside: -15.99%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $70.07
Upside: +78.39%
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $491.47
Upside: +14.76%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.39
Upside: +21.79%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $45.19
Upside: +19.50%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $105.87
Upside: +23.74%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $473.66
Upside: -8.16%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $11.65
Upside: -5.58%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $53.07
Upside: -39.70%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $11.87
Upside: -7.33%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.89
Upside: +323.28%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $196.52
Upside: +121.86%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $314.40
Upside: -